"Designing Growth Strategies is in our DNA"

Endocrinology Drugs Market Size, Share & Industry Analysis, By Drug Class (Diabetes & Metabolic {Insulins, GLP-1 Receptor Agonists, and SGLT2 Inhibitors}, Thyroid {Thyroid Hormones and Antithyroid Agents}, Pituitary {Growth Hormones}, Adrenal {Glucocorticoids}, and Bone Metabolism {Bisphosphonates}), By Disease Indication (Diabetes Mellitus, Obesity, and Thyroid Disorders), By Age Group (Pediatric and Adults), By Route of Administration (Oral, Subcutaneous, Intravenous, and Others), By Distribution Channel (Hospital, Retail, and Specialty Pharmacies), and Regional Forecast, 2026-2034

Last Updated: October 09, 2026 | Format: PDF | Report ID: FBI119383

 

Buy Now

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Endocrine Disorders, By Key Regions/Countries
    2. Overview: Regulatory & Reimbursement Scenario, By Key Regions/Countries
    3. New Product Launches, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
    5. PESTEL Analysis
    6. Porter’s Five Force Model
  5. Global Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class    
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication   
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration       
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel              
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Eli Lilly and Company
      2. Novo Nordisk A/S
      3. Amgen Inc.
      4. Boehringer Ingelheim International GmbH
      5. Sanofi
      6. AstraZeneca PLC
      7. Merck & Co., Inc.
      8. Sandoz Group AG
      9. AbbVie Inc.
      10. Pfizer Inc.
      11. Teva Pharmaceutical Industries Ltd.
      12. Biocon Biologics Limited
      13. Ascendis Pharma A/S
      14. Gan & Lee Pharmaceuticals Co., Ltd.
      15. Recordati Industria Chimica e Farmaceutica S.p.A.
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Endocrine Disorders, By Key Regions/Countries
    2. Overview: Regulatory & Reimbursement Scenario, By Key Regions/Countries
    3. New Product Launches, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
    5. PESTEL Analysis
    6. Porter’s Five Force Model
  5. Global Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class 
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication                
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration    
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel           
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Endocrinology Drugs Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug Class    
      1. Diabetes and Metabolic Drug Classes
        1. Insulins & Insulin Analogues
        2. GLP-1 Receptor Agonists
        3. Dual & Multi-Receptor Agonists
        4. SGLT2 Inhibitors
        5. Others
      2. Thyroid Drug Classes
        1. Thyroid Hormones
        2. Antithyroid Agents
        3. IGF-1 Receptor Inhibitors
        4. Others
      3. Pituitary and Hypothalamic Drug Classes
        1. Growth Hormones
        2. Somatostatin Analogues
        3. Vasopressin Analogues
        4. Dopamine Agonists
        5. Others
      4. Adrenal Drug Classes
        1. Glucocorticoids
        2. Mineralocorticoids
        3. Steroidogenesis Inhibitors
        4. Glucocorticoid Receptor Antagonists & Modulators
        5. Others
      5. Bone and Mineral Metabolism Drug Classes
        1. Bisphosphonates
        2. RANKL Inhibitors
        3. Parathyroid Hormone & PTHrP Analogues
        4. Sclerostin Inhibitors
        5. Others
      6. Gonadal and Pubertal Drug Classes
        1. Androgens
        2. Estrogens
        3. Progestogens
        4. GnRH Agonists
        5. Others
      7. Other Drug Classes
        1. Glucagon & Glucagon Analogues
        2. Calcimimetics
        3. FGF23 Inhibitors
        4. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication   
      1. Diabetes Mellitus
      2. Obesity & Weight Management
      3. Thyroid Disorders
      4. Osteoporosis & Other Metabolic Bone Disorders
      5. Gonadal & Pubertal Disorders
      6. Pituitary & Hypothalamic Disorders
      7. Adrenal Disorders
      8. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    4. Market Analysis, Insights and Forecast – By Route of Administration       
      1. Oral
      2. Subcutaneous
      3. Intravenous
      4. Transdermal
      5. Others
    5. Market Analysis, Insights and Forecast – By Distribution Channel              
      1. Hospital Pharmacies
      2. Retail Pharmacies & Drug Stores
      3. Specialty Pharmacies
      4. Others
    6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Eli Lilly and Company
      2. Novo Nordisk A/S
      3. Amgen Inc.
      4. Boehringer Ingelheim International GmbH
      5. Sanofi
      6. AstraZeneca PLC
      7. Merck & Co., Inc.
      8. Sandoz Group AG
      9. AbbVie Inc.
      10. Pfizer Inc.
      11. Teva Pharmaceutical Industries Ltd.
      12. Biocon Biologics Limited
      13. Ascendis Pharma A/S
      14. Gan & Lee Pharmaceuticals Co., Ltd.
      15. Recordati Industria Chimica e Farmaceutica S.p.A.
Read Less

Figure 1: Global Endocrinology Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 2: Global Endocrinology Drugs Market Value Share (%), by Drug Class, 2025 & 2034

Figure 3: Global Endocrinology Drugs Market Value Share (%), by Disease Indication, 2025 & 2034

Figure 4: Global Endocrinology Drugs Market Value Share (%), by Age Group, 2025 & 2034

Figure 5: Global Endocrinology Drugs Market Value Share (%), by Route of Administration, 2025 & 2034

Figure 6: Global Endocrinology Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 7: Global Endocrinology Drugs Market Value Share (%), by Region, 2025 & 2034

Figure 8: North America Endocrinology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 9: North America Endocrinology Drugs Market Value Share (%), by Drug Class, 2025

Figure 10: North America Endocrinology Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 11: North America Endocrinology Drugs Market Value Share (%), by Disease Indication, 2025

Figure 12: North America Endocrinology Drugs Market Value (USD billion), by Age Group, 2025 & 2034

Figure 13: North America Endocrinology Drugs Market Value Share (%), by Age Group, 2025

Figure 14: North America Endocrinology Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 15: North America Endocrinology Drugs Market Value Share (%), by Route of Administration, 2025

Figure 16: North America Endocrinology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 17: North America Endocrinology Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 18: North America Endocrinology Drugs Market Value (USD billion), by Country, 2025 & 2034

Figure 19: North America Endocrinology Drugs Market Value Share (%), by Country, 2025

Figure 20: Europe Endocrinology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 21: Europe Endocrinology Drugs Market Value Share (%), by Drug Class, 2025

Figure 22: Europe Endocrinology Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 23: Europe Endocrinology Drugs Market Value Share (%), by Disease Indication, 2025

Figure 24: Europe Endocrinology Drugs Market Value (USD billion), by Age Group, 2025 & 2034

Figure 25: Europe Endocrinology Drugs Market Value Share (%), by Age Group, 2025

Figure 26: Europe Endocrinology Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 27: Europe Endocrinology Drugs Market Value Share (%), by Route of Administration, 2025

Figure 28: Europe Endocrinology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 29: Europe Endocrinology Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 30: Europe Endocrinology Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 31: Europe Endocrinology Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 32: Asia Pacific Endocrinology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 33: Asia Pacific Endocrinology Drugs Market Value Share (%), by Drug Class, 2025

Figure 34: Asia Pacific Endocrinology Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 35: Asia Pacific Endocrinology Drugs Market Value Share (%), by Disease Indication, 2025

Figure 36: Asia Pacific Endocrinology Drugs Market Value (USD billion), by Age Group, 2025 & 2034

Figure 37: Asia Pacific Endocrinology Drugs Market Value Share (%), by Age Group, 2025

Figure 38: Asia Pacific Endocrinology Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 39: Asia Pacific Endocrinology Drugs Market Value Share (%), by Route of Administration, 2025

Figure 40: Asia Pacific Endocrinology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 41: Asia Pacific Endocrinology Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 42: Asia Pacific Endocrinology Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 43: Asia Pacific Endocrinology Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 44: Latin America Endocrinology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 45: Latin America Endocrinology Drugs Market Value Share (%), by Drug Class, 2025

Figure 46: Latin America Endocrinology Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 47: Latin America Endocrinology Drugs Market Value Share (%), by Disease Indication, 2025

Figure 48: Latin America Endocrinology Drugs Market Value (USD billion), by Age Group, 2025 & 2034

Figure 49: Latin America Endocrinology Drugs Market Value Share (%), by Age Group, 2025

Figure 50: Latin America Endocrinology Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 51: Latin America Endocrinology Drugs Market Value Share (%), by Route of Administration, 2025

Figure 52: Latin America Endocrinology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 53: Latin America Endocrinology Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 54: Latin America Endocrinology Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 55: Latin America Endocrinology Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 56: Middle East & Africa Endocrinology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034

Figure 57: Middle East & Africa Endocrinology Drugs Market Value Share (%), by Drug Class, 2025

Figure 58: Middle East & Africa Endocrinology Drugs Market Value (USD billion), by Disease Indication, 2025 & 2034

Figure 59: Middle East & Africa Endocrinology Drugs Market Value Share (%), by Disease Indication, 2025

Figure 60: Middle East & Africa Endocrinology Drugs Market Value (USD billion), by Age Group, 2025 & 2034

Figure 61: Middle East & Africa Endocrinology Drugs Market Value Share (%), by Age Group, 2025

Figure 62: Middle East & Africa Endocrinology Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 63: Middle East & Africa Endocrinology Drugs Market Value Share (%), by Route of Administration, 2025

Figure 64: Middle East & Africa Endocrinology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 65: Middle East & Africa Endocrinology Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 66: Middle East & Africa Endocrinology Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 67: Middle East & Africa Endocrinology Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 68: Global Endocrinology Drugs Market Share (%), by Company, 2025

Table 1: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 2: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Diabetes and Metabolic Drug Classes, 2021–2034

Table 3: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Thyroid Drug Classes, 2021–2034

Table 4: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Pituitary and Hypothalamic Drug Classes, 2021–2034

Table 5: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Adrenal Drug Classes, 2021–2034

Table 6: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Bone and Mineral Metabolism Drug Classes, 2021–2034

Table 7: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Gonadal and Pubertal Drug Classes, 2021–2034

Table 8: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Other Drug Classes, 2021–2034

Table 9: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Disease Indication, 2021–2034

Table 10: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 11: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 12: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 13: Global Endocrinology Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 14: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 15: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Diabetes and Metabolic Drug Classes, 2021–2034

Table 16: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Thyroid Drug Classes, 2021–2034

Table 17: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Pituitary and Hypothalamic Drug Classes, 2021–2034

Table 18: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Adrenal Drug Classes, 2021–2034

Table 19: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Bone and Mineral Metabolism Drug Classes, 2021–2034

Table 20: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Gonadal and Pubertal Drug Classes, 2021–2034

Table 21: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Other Drug Classes, 2021–2034

Table 22: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Disease Indication, 2021–2034

Table 23: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 24: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 25: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 26: North America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034

Table 27: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 28: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Diabetes and Metabolic Drug Classes, 2021–2034

Table 29: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Thyroid Drug Classes, 2021–2034

Table 30: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Pituitary and Hypothalamic Drug Classes, 2021–2034

Table 31: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Adrenal Drug Classes, 2021–2034

Table 32: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Bone and Mineral Metabolism Drug Classes, 2021–2034

Table 33: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Gonadal and Pubertal Drug Classes, 2021–2034

Table 34: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Other Drug Classes, 2021–2034

Table 35: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Disease Indication, 2021–2034

Table 36: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 37: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 38: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 39: Europe Endocrinology Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 40: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 41: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Diabetes and Metabolic Drug Classes, 2021–2034

Table 42: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Thyroid Drug Classes, 2021–2034

Table 43: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Pituitary and Hypothalamic Drug Classes, 2021–2034

Table 44: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Adrenal Drug Classes, 2021–2034

Table 45: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Bone and Mineral Metabolism Drug Classes, 2021–2034

Table 46: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Gonadal and Pubertal Drug Classes, 2021–2034

Table 47: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Other Drug Classes, 2021–2034

Table 48: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Disease Indication, 2021–2034

Table 49: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 50: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 51: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 52: Asia Pacific Endocrinology Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 53: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 54: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Diabetes and Metabolic Drug Classes, 2021–2034

Table 55: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Thyroid Drug Classes, 2021–2034

Table 56: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Pituitary and Hypothalamic Drug Classes, 2021–2034

Table 57: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Adrenal Drug Classes, 2021–2034

Table 58: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Bone and Mineral Metabolism Drug Classes, 2021–2034

Table 59: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Gonadal and Pubertal Drug Classes, 2021–2034

Table 60: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Other Drug Classes, 2021–2034

Table 61: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Disease Indication, 2021–2034

Table 62: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 63: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 64: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 65: Latin America Endocrinology Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 66: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021–2034

Table 67: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Diabetes and Metabolic Drug Classes, 2021–2034

Table 68: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Thyroid Drug Classes, 2021–2034

Table 69: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Pituitary and Hypothalamic Drug Classes, 2021–2034

Table 70: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Adrenal Drug Classes, 2021–2034

Table 71: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Bone and Mineral Metabolism Drug Classes, 2021–2034

Table 72: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Gonadal and Pubertal Drug Classes, 2021–2034

Table 73: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Other Drug Classes, 2021–2034

Table 74: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Disease Indication, 2021–2034

Table 75: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Age Group, 2021–2034

Table 76: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 77: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 78: Middle East & Africa Endocrinology Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Endocrinology Drugs Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon
    Mail icon

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Customize Now
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports